Biomedicines (May 2023)

Hereditary Breast Cancer in Romania—Molecular Particularities and Genetic Counseling Challenges in an Eastern European Country

  • Andreea Cătană,
  • Adrian P. Trifa,
  • Patriciu A. Achimas-Cadariu,
  • Gabriela Bolba-Morar,
  • Carmen Lisencu,
  • Eniko Kutasi,
  • Vlad F. Chelaru,
  • Maximilian Muntean,
  • Daniela L. Martin,
  • Nicoleta Z. Antone,
  • Bogdan Fetica,
  • Florina Pop,
  • Mariela S. Militaru

DOI
https://doi.org/10.3390/biomedicines11051386
Journal volume & issue
Vol. 11, no. 5
p. 1386

Abstract

Read online

In Romania, breast cancer (BC) is the most common malignancy in women. However, there is limited data on the prevalence of predisposing germline mutations in the population in the era of precision medicine, where molecular testing has become an indispensable tool in cancer diagnosis, prognosis, and therapeutics. Therefore, we conducted a retrospective study to determine the prevalence, mutational spectrum, and histopathological prediction factors for hereditary breast cancer (HBC) in Romania. A cohort of 411 women diagnosed with BC selected upon NCCN v.1.2020 guidelines underwent an 84-gene NGS-based panel testing for breast cancer risk assessment during 2018–2022 in the Department of Oncogenetics of the Oncological Institute of Cluj-Napoca, Romania. A total of 135 (33%) patients presented pathogenic mutations in 19 genes. The prevalence of genetic variants was determined, and demographic and clinicopathological characteristics were analyzed. We observed differences among BRCA and non-BRCA carriers regarding family history of cancer, age of onset, and histopathological subtypes. Triple-negative (TN) tumors were more often BRCA1 positive, unlike BRCA2 positive tumors, which were more often the Luminal B subtype. The most frequent non-BRCA mutations were found in CHEK2, ATM, and PALB2, and several recurrent variants were identified for each gene. Unlike other European countries, germline testing for HBC is still limited due to the high costs and is not covered by the National Health System (NSH), thus leading to significant discrepancies related to the screening and prophylaxis of cancer.

Keywords